Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
52.20
-0.20 (-0.38%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
64
65
Next >
Bristol Myers Squibb Announces Dividend
June 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
June 10, 2024
Via
Benzinga
Smart Money Is Betting Big In BMY Options
June 07, 2024
Via
Benzinga
6% Yield Bristol Myers Squibb Value Trap Or Long-Term Opportunity?
May 31, 2024
BMY is offering a 6% yield and trading for less than 9 times earnings.
Via
Talk Markets
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
June 15, 2024
Their prices might not be done falling, but you can count on the dividends they distribute to continue rising steadily.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
3 High-Yield Dividend Stocks for Income Now and Growth Later
June 14, 2024
Buying high-yield dividend stocks at a low price today gives you current income with the opportunity for growth when interest rates come down later this year
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking
May 30, 2024
Via
Benzinga
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
June 13, 2024
From
Bristol Myers Squibb
Via
Business Wire
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
June 11, 2024
These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential.
Via
InvestorPlace
7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too)
June 10, 2024
Here are seven Warren Buffett stocks to sell that the Oracle himself has decided that they've lost their luster.
Via
InvestorPlace
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
June 08, 2024
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...
Via
Talk Markets
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
June 08, 2024
Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder
Via
InvestorPlace
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
June 07, 2024
FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusion-dependent anemia Geron's first commercial treatment targets a market...
Via
Benzinga
Exposures
Product Safety
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
June 06, 2024
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was...
Via
Benzinga
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients
June 04, 2024
Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC.
Via
Benzinga
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday
June 03, 2024
Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated NSCLC, improving progression-free survival and response rates.
Via
Benzinga
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
June 03, 2024
This pair of high-yield dividend payers offer yields near 6% and a chance for steady payout raises in the years to come.
Via
The Motley Fool
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
June 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
May 31, 2024
FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, marking its fourth non-Hodgkin lymphoma subtype indication.
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
May 31, 2024
Via
Benzinga
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
May 30, 2024
From
Bristol Myers Squibb
Via
Business Wire
7 Underappreciated Stocks With 25% Return Potential in 2024
May 30, 2024
Each of these underappreciated stocks is expected to provide 25%+ returns this year, which is reason enough to pay attention.
Via
InvestorPlace
Are Boomers Crashing The Economy Or Saving It? Why Investors Are Perplexed And What You Can Do To Prepare
May 29, 2024
Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest wealth transfer in history.
Via
Benzinga
Topics
Economy
Retirement
Exposures
Economy
Pension
< Previous
1
2
3
4
5
6
7
8
9
...
64
65
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.